Technical Analysis for MNKD - MannKind Corporation
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Flat |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New Uptrend | Bullish | 0.00% | |
| Calm After Storm | Range Contraction | 0.00% | |
| Outside Day | Range Expansion | -2.49% | |
| Gapped Up | Strength | -2.49% | |
| Calm After Storm | Range Contraction | -3.78% | |
| Stochastic Sell Signal | Bearish | -1.93% | |
| Calm After Storm | Range Contraction | -1.93% | |
| Upper Bollinger Band Walk | Strength | -1.93% | |
| Overbought Stochastic | Strength | -1.93% | |
| Jack-in-the-Box Bullish | Bullish Swing Setup | -2.86% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakdown | about 6 hours ago |
| Fell Below 10 DMA | about 8 hours ago |
| 10 DMA Support | about 10 hours ago |
| Down 3% | about 10 hours ago |
| Fell Below Previous Day's Low | about 10 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 08/05/2024
MannKind Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diabetes and cancer in the United States. Its lead product candidate includes AFREZZA inhalation powder, an insulin that is in late-stage clinical investigation for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia. The company also develops MedTone and Dreamboat inhaler devices. MannKind Corporation was founded in 1991 and is headquartered in Valencia, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Organ Systems Boat Diabetes Therapeutic Products Insulin Endocrine System Hyperglycemia Inhaler
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Organ Systems Boat Diabetes Therapeutic Products Insulin Endocrine System Hyperglycemia Inhaler
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 5.75 |
| 52 Week Low | 3.17 |
| Average Volume | 2,349,367 |
| 200-Day Moving Average | 4.11 |
| 50-Day Moving Average | 4.62 |
| 20-Day Moving Average | 4.90 |
| 10-Day Moving Average | 5.10 |
| Average True Range | 0.22 |
| RSI (14) | 56.33 |
| ADX | 25.47 |
| +DI | 31.83 |
| -DI | 14.96 |
| Chandelier Exit (Long, 3 ATRs) | 4.88 |
| Chandelier Exit (Short, 3 ATRs) | 5.03 |
| Upper Bollinger Bands | 5.44 |
| Lower Bollinger Band | 4.36 |
| Percent B (%b) | 0.68 |
| BandWidth | 22.04 |
| MACD Line | 0.17 |
| MACD Signal Line | 0.15 |
| MACD Histogram | 0.0221 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 5.48 | ||||
| Resistance 3 (R3) | 5.50 | 5.38 | 5.42 | ||
| Resistance 2 (R2) | 5.38 | 5.28 | 5.38 | 5.39 | |
| Resistance 1 (R1) | 5.24 | 5.22 | 5.18 | 5.22 | 5.37 |
| Pivot Point | 5.12 | 5.12 | 5.10 | 5.12 | 5.12 |
| Support 1 (S1) | 4.98 | 5.02 | 4.92 | 4.96 | 4.81 |
| Support 2 (S2) | 4.86 | 4.96 | 4.86 | 4.79 | |
| Support 3 (S3) | 4.72 | 4.86 | 4.77 | ||
| Support 4 (S4) | 4.70 |
